ERBB2 and cancer: In brief, the integration of inclisiran into cardio-oncology practice warrants further investigation, particularly through randomized controlled trials assessing its impact on long-term cardiac outcomes in cancer patients undergoing sequential anthracycline and HER2-targeted therapies [48].